new technologies competing with glp-1 medications 2025 The next phase of the obesity drug race GLP-1 Receptor Agonist Market Size

At a 2025 longevity conference in Las Vegas, two women ended up on ventilators after being injected with peptides the FDA had flagged as unsafe

We provide transparent information about Peptide Therapies, their benefits, potential risks, and what to expect during treatment

According to data presented at the AASLD Liver Meeting in November 2024, semaglutide has shown significant efficacy in managing liver inflammation and fibrosis in a phase III clinical trial

Wild blueberry (poly)phenols can improve vascular function and cognitive performance in healthy older individuals: a double-blind randomized controlled trial

, , , M-Group

27 In a case-control study, Niazi et al compared 1,737 patients with glaucoma with 8,685 controls without glaucoma